TABLE 1.
Months from diagnosis to first suppressed viral loada |
|||||||
---|---|---|---|---|---|---|---|
≤12 | ≤24 | ||||||
Characteristic | Linkage to care | No. | % | Mean | % | % | p-valueb |
Total | Within 1 month | 16,801 | 64.6 | 15.4 | 64.9 | 76.1 | |
Within 2–3 months | 3,771 | 14.5 | 18.1 | 58.2 | 72.7 | <.0001 | |
Within 3 months | 20,572 | 79 | 15.9 | 63.6 | 75.5 | NA | |
Not linked to care | 5,454 | 21 | 34.0 | 17.0 | 32.7 | NA | |
Sex | |||||||
Male | Within 1 month | 13,261 | 64.1 | 15.6 | 64.6 | 75.9 | |
Within 2–3 months | 2,980 | 14.4 | 18.4 | 56.9 | 72.3 | <.0001 | |
Within 3 months | 16,241 | 78.6 | 16.1 | 63.2 | 75.2 | NA | |
Not linked to care | 4,433 | 21.4 | 33.5 | 16.4 | 32.8 | NA | |
Female | Within 1 month | 3,540 | 66.1 | 14.8 | 65.8 | 77.1 | |
Within 2–3 months | 791 | 14.8 | 16.1 | 63.0 | 73.9 | <.0001 | |
Within 3 months | 4,331 | 80.9 | 15.2 | 65.3 | 76.6 | NA | |
Not linked to care | 1,021 | 19.1 | 34.1 | 19.5 | 32.2 | NA | |
Race/ethnicity | |||||||
Black/African American | Within 1 month | 7,432 | 60.8 | 17.6 | 58.9 | 71 | |
Within 2–3 months | 1,809 | 14.8 | 19.2 | 54.4 | 68.3 | <.0001 | |
Within 3 months | 9,241 | 75.6 | 18 | 58 | 70.5 | NA | |
Not linked to care | 2,976 | 24.4 | 34.7 | 16.1 | 30.9 | NA | |
Hispanic/Latino | Within 1 month | 3,797 | 66.5 | 14.1 | 69.1 | 79.1 | |
Within 2–3 months | 783 | 13.7 | 15.9 | 63.8 | 77.3 | <.0001 | |
Within 3 months | 4,580 | 80.2 | 14.5 | 68.2 | 78.8 | NA | |
Not linked to care | 1,134 | 19.8 | 32.8 | 16.6 | 31.3 | NA | |
White | Within 1 month | 4,497 | 68.9 | 13.4 | 69.5 | 81.2 | |
Within 2–3 months | 959 | 14.7 | 16.7 | 60.7 | 77 | <.0001 | |
Within 3 months | 5,456 | 83.6 | 14 | 68 | 80.4 | NA | |
Not linked to care | 1,068 | 16.4 | 31.4 | 19.5 | 37.8 | NA | |
Age at diagnosis | |||||||
13–24 | Within 1 month | 3,219 | 56.8 | 18.2 | 57 | 70.1 | |
Within 2–3 months | 966 | 17 | 20.2 | 51 | 67.1 | <.0001 | |
Within 3 months | 4,185 | 73.8 | 18.7 | 55.6 | 69.4 | NA | |
Not linked to care | 1,484 | 26.2 | 33.7 | 15.6 | 32.5 | NA | |
25–34 | Within 1 month | 4,620 | 62.1 | 16.2 | 62.9 | 74.6 | |
Within 2–3 months | 1,151 | 15.5 | 18.3 | 57.3 | 72.3 | <.0001 | |
Within 3 months | 5,771 | 77.6 | 16.6 | 61.8 | 74.1 | NA | |
Not linked to care | 1,670 | 22.4 | 33.4 | 15.5 | 31.1 | NA | |
35–44 | Within 1 month | 3,987 | 67.8 | 14.5 | 67.7 | 78.4 | |
Within 2–3 months | 804 | 13.7 | 15.9 | 62 | 75.7 | <.0001 | |
Within 3 months | 4,791 | 81.5 | 14.9 | 66.8 | 78 | NA | |
Not linked to care | 1,089 | 18.5 | 34 | 16.9 | 31.8 | NA | |
45–54 | Within 1 month | 3,359 | 70.1 | 13.5 | 69.7 | 79.8 | |
Within 2–3 months | 611 | 12.8 | 16.1 | 63.1 | 76.6 | <.0001 | |
Within 3 months | 3,970 | 82.9 | 14 | 68.6 | 79.3 | NA | |
Not linked to care | 821 | 17.1 | 31.1 | 19.7 | 36.7 | NA | |
>=55 | Within 1 month | 1,616 | 72 | 13.3 | 70.1 | 80.1 | |
Within 2–3 months | 239 | 10.6 | 13.6 | 67.2 | 77.6 | <.001 | |
Within 3 months | 1,855 | 82.6 | 13.6 | 69.7 | 79.8 | NA | |
Not linked to care | 390 | 17.4 | 32.7 | 25 | 34.1 | NA | |
Transmission category | |||||||
Male-to-male sexual contact | Within 1 month | 9,119 | 65.2 | 15.1 | 65.7 | 77.2 | |
Within 2–3 months | 2,143 | 15.3 | 18 | 57 | 72.6 | <.0001 | |
Within 3 months | 11,262 | 80.5 | 15.7 | 64 | 76.3 | NA | |
Not linked to care | 2,734 | 19.5 | 32.2 | 17.4 | 36.2 | NA | |
Injection drug use | Within 1 month | 692 | 63.4 | 17.5 | 60 | 70.4 | |
Within 2–3 months | 140 | 12.8 | 16.8 | 61.3 | 73.9 | 0.228 | |
Within 3 months | 832 | 76.3 | 17.5 | 60.2 | 71 | NA | |
Not linked to care | 259 | 23.7 | 33.4 | 16 | 29.9 | NA | |
Male-to-male sexual contact and injection drug use | Within 1 month | 444 | 63.9 | 16.3 | 60.4 | 74.1 | |
Within 2–3 months | 130 | 18.7 | 18.8 | 51.1 | 75.8 | <.01 | |
Within 3 months | 574 | 82.6 | 17 | 58.3 | 74.5 | NA | |
Not linked to care | 121 | 17.4 | 31.2 | 19.1 | 37.8 | NA | |
Heterosexual contact | Within 1 month | 2,428 | 65.9 | 14.4 | 66.1 | 78 | |
Within 2–3 months | 600 | 16.3 | 17.1 | 59.1 | 72.7 | <.0001 | |
Within 3 months | 3,028 | 82.2 | 15 | 64.7 | 77 | NA | |
Not linked to care | 655 | 17.8 | 31.5 | 20.2 | 37.2 | NA |
N = 26,026
Suppressed viral load defined as ≤200 copies/mL.
Wilcoxon test of equality over strata 1 months vs. 2–3 months.